霍奇金淋巴瘤与非霍奇金淋巴瘤的诊断、分期及疗效评估影像学
本文综述儿童霍奇金淋巴瘤与非霍奇金淋巴瘤的影像学应用,涵盖CT、MRI及PET/CT、PET/MRI在诊断、分期和疗效评估中的作用。儿童淋巴瘤均FDG高摄取,分期评估需PET/CT或PET/MRI;早期或中期PET阴性是预后良好的可靠指标,但影像可能无法预测复发。
要点
- 儿童淋巴瘤分期评估需行FDG PET/CT或PET/MRI,可识别淋巴结、实体器官、皮质骨及骨髓病变。
- 霍奇金淋巴瘤采用Ann Arbor系统伴Cotswold修改,非霍奇金淋巴瘤采用Murphy St. Jude分类或IPNHLSS。
- 早期或中期PET阴性是临床结局改善的可靠指标,可优化风险适应治疗,但影像可能无法预测复发。
核心结论
- 儿童霍奇金淋巴瘤和非霍奇金淋巴瘤均为FDG高摄取,分期评估需FDG PET/CT或PET/MRI。
- 早期或中期PET阴性扫描是临床结局改善的可靠指标,可优化风险适应治疗和患者管理,但影像可能无法预测谁将复发。
研究设计与样本
- 综述,未报告系统检索范围与纳入文献数量。
- 涉及常规CT、MRI及代谢影像PET/CT和PET/MRI。
- 参考标准包括Ann Arbor系统伴Cotswold修改(霍奇金淋巴瘤)、Murphy St. Jude分类或修订国际儿童非霍奇金淋巴瘤分期系统(IPNHLSS)(非霍奇金淋巴瘤)。
关键影像表现/征象
- 横断面影像可显示腹部淋巴结组和器官受累,已取代分期剖腹术和脾切除术。
- FDG PET提供骨髓受累信息,MRI可阐明皮质骨细节并确认骨髓受累。
- 两种疾病就诊时均可有影像显示的气道受压问题。
- 霍奇金淋巴瘤影像可见独立不良预后因素:大纵隔淋巴结病、IV期疾病、全身症状、胸腔积液和心包积液。
- 非霍奇金淋巴瘤更多累及肾脏、卵巢、中枢神经系统和皮肤等器官。
诊断标准与关键数值
- 霍奇金淋巴瘤分期采用Ann Arbor系统伴Cotswold修改,基于影像。
- 非霍奇金淋巴瘤分期采用Murphy St. Jude分类或修订国际儿童非霍奇金淋巴瘤分期系统(IPNHLSS)。
- 疗效评估系统包括Deauville视觉量表(摄取与肝脏比较)、Lugano系统(包含大小变化)或定量PET(使用标准化摄取值定义更准确的反应)。
临床应用与阅片要点
- 近期多中心试验结论认为,儿童淋巴瘤分期和中期评估通常足以采用从颅底到大腿中部的PET成像。
- 免疫治疗新方法可能因炎症改变在FDG PET评估中产生挑战,炎症改变可能不代表疾病。
局限性
- 影像可能无法预测谁将复发。
- 免疫治疗新方法可能因炎症改变在FDG PET评估中产生挑战。
- 近期多中心试验结论认为分期和中期评估通常足以采用从颅底到大腿中部的PET成像,原文未报告该试验的具体样本量、中心数及统计学细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Hodgkin lymphoma and non-Hodgkin lymphoma are common malignancies in children and are now highly treatable. Imaging plays a major role in diagnosis, staging and response using conventional CT and MRI and metabolic imaging with positron emission tomography (PET)/CT and PET/MRI. Cross-sectional imaging has replaced staging laparotomy and splenectomy by demonstrating abdominal nodal groups and organ involvement. [F-18]2-fluoro-2-deoxyglucose (FDG) PET provides information on bone marrow involvement, and MRI elucidates details of cortical bone and confirmation of bone marrow involvement. The staging system for Hodgkin lymphoma is the Ann Arbor system with Cotswald modifications and is based on imaging, whereas the non-Hodgkin staging system is the St. Jude Classification by Murphy or the more recent revised International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS). Because all pediatric lymphomas are metabolically FDG-avid and identify all nodal, solid organ, cortical bone and bone marrow disease, staging evaluations require FDG PET as PET/CT or PET/MRI in both Hodgkin and non-Hodgkin lymphoma. Both diseases have in common issues of airway compromise at presentation demonstrated by imaging. Differences exist in that Hodgkin lymphoma has several independent poor prognostic factors seen by imaging such as large mediastinal adenopathy, Stage IV disease, systemic symptoms, pleural effusion and pericardial effusion. Non-Hodgkin lymphoma includes more organ involvement such as renal, ovary, central nervous system and skin. Early or interim PET-negative scans are a reliable indicator of improved clinical outcome and optimize risk-adapted therapy and patient management; imaging may not, however, predict who will relapse. A recent multicenter trial has concluded that it is usually sufficient for pediatric lymphoma at staging and interim assessment to evaluate children with PET imaging from skull base to mid-thigh. Various systems of assessment of presence of disease or response are used, including the Deauville visual scale, where avidity is compared to liver; Lugano, which includes size change as part of response; or quantitative PET, which uses standardized uptake values to define more accurate response. Newer methods of immunotherapy can produce challenges in FDG PET evaluation because of inflammatory changes that may not represent disease.
引用
- McCarten KM, Nadel HR, Shulkin BL, et al. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatr Radiol. 2019. PMID: 31620854. doi:10.1007/s00247-019-04529-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。